# Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Study · id `cardio:ct-nct03130426` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03130426](<https://clinicaltrials.gov/study/NCT03130426>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03130426

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

## Technical summary

Registry record NCT03130426. Randomized; no masking; primary purpose treatment. Start 2017-06-27 (actual); primary completion 2019-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 161 participants (enrolled count; ClinicalTrials.gov record NCT03130426, source copy `cardio:ctgov-nct03130426-2020-11-13`, retrieved 2026-10-26)
- Started: 2017-06-27 (actual) (ClinicalTrials.gov record NCT03130426, source copy `cardio:ctgov-nct03130426-2020-11-13`, retrieved 2026-10-26)
- Primary completion: 2019-06-30 (actual) (ClinicalTrials.gov record NCT03130426, source copy `cardio:ctgov-nct03130426-2020-11-13`, retrieved 2026-10-26)
- Completion: 2020-09-30 (actual) (ClinicalTrials.gov record NCT03130426, source copy `cardio:ctgov-nct03130426-2020-11-13`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT03130426, source copy `cardio:ctgov-nct03130426-2020-11-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03130426-2020-11-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
- Acronym: REMIT-iGL
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): iGlarLixi
- Intervention (Drug): Insulin Glargine
- Intervention (Drug): Metformin
- Intervention (Behavioral): Lifestyle therapy
- Lead sponsor: Population Health Research Institute
- Lead sponsor class: OTHER
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Population Health Research Institute (`cardio:org-population-health-research-institute`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 10bdf55ad848bc4223478d0025612978c28fe3c6da6ecb4aa9a04ca41fabed47
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
